Niagen Bioscience Inc
NAGE
Get informed when a big investor buys or sells
+ FollowMarket Cap$611.9M
Close$
Share Statistics
| Market cap | $611.90 Million |
|---|---|
| Enterprise Value | $547.81 Million |
| Dividend Yield | $NaN (NaN%) |
| Earnings per Share | $- |
| Beta | - |
| Outstanding Shares | - |
Return
| Return on Equity | 19.38% |
|---|---|
| Return on Assets | 15.00% |
| Return on Invested Capital | 11.98% |
Valuation & Multiples
| P/E Ratio | - |
|---|---|
| PEG | - |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 18.39 |
| Enterprise Value to EBIT | 49.95 |
| Enterprise Value to Net Income | 34 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.03 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 4, 2026
EPS Estimate
$0.01
Average shareholder expectationRevenue Estimate
$30.53 M
Average shareholder expectationNext Earnings Call
Expected Date
November 3, 2026
EPS Estimate
$0.01
Average shareholder expectationRevenue Estimate
$34.45 M
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Chromadex Corp
117 employees
CEO: Robert Fried ChromaDex Corp. is a science-based integrated nutraceutical company devoted to improving the way people age. ChromaDex scientists partner with leading universities and research institutions worldwide to discover, develop and create solut...